The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letters to the EditorFull Access

COVID-19, Medication-Assisted Treatment, and Increased Risk for Further Respiratory Depression

To the Editor: The COVID-19 infection is characterized by respiratory distress, which has sparked Herculean efforts to increase the supply of ventilators in the United States. Even as the medical establishment races to cope with this pandemic, clinical authorities continue to emphasize the need for opioid agonist treatment, more commonly known as medication-assisted treatment, which includes methadone and buprenorphine. In fact, longstanding rules are now being relaxed to allow people receiving medication-assisted treatment to receive a full 28-day supply of their medication to decrease the spread of the novel coronavirus at treatment centers. Medication-assisted treatment has been demonstrated to significantly decrease mortality associated with substance use. In their recent epidemiological study, Pearce et al. demonstrated that the relative risk of mortality off of medication-assisted treatment was 2.1 (1).

In considering the overall health of Americans, including those with known respiratory compromise secondary to long-term tobacco use, asthma, and bronchitis, as well as chronic obstructive pulmonary disease in the elderly and the possibility of respiratory compromise related to vaping among the young, it is important to remember that many of these same patients are also taking prescribed opiates and/or may be misusing opiates. Further, it is essential that those prescribing medication-assisted treatment are acutely aware that these opiate agonists and agonist/antagonists are also capable of causing significant respiratory distress (2). Finally, it is important to remember that benzodiazepines (especially when combined with opiates) are associated with respiratory depression in patients with other respiratory challenges (3).

Patients prescribed opiates and benzodiazepines should be advised of these risks and collaborate with their care team to establish the lowest effective dosage of their medications during this pandemic. If nothing else, it is always prudent to periodically review dosages of controlled substances to ensure safety and satisfaction. In cases in which the patient becomes symptomatic and/or has tested positive for COVID-19, clinicians are advised to discuss at least temporarily decreasing the dosage and quantity of prescribed opiates or medication-assisted treatment. In addition, clinicians need to be aware of the availability and value of naltrexone inhalers, which, if prescribed, could prove lifesaving in a patient with respiratory compromise that has been exacerbated by an opiate or opioid agonist treatment.

West Texas Health Care System, Big Spring.
Send correspondence to Dr. Boyer ().

The contents of the letter reflect the opinion of the author and do not in any way represent the views or policies of the U.S. Department of Veterans Affairs or the U.S. government.

The author reports no financial relationships with commercial interests.

References

1 Pearce LA, Min JE, Piske M, et al.: Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ 2020; 368:m772Crossref, MedlineGoogle Scholar

2 Substance Abuse and Mental Health Services Administration: Promoting Safety from Opioid Overdose. June 20, 2018. https://blog.samhsa.gov/2018/06/20/promoting-safety-from-opioid-overdoseGoogle Scholar

3 American Society of Addiction Medicine: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2Google Scholar